Lunsumio

(Mosunetuzumab-axgb)

Lunsumio

Drug updated on 1/19/2024

Dosage FormInjection (intravenous; 1 mg/mL, 30 mg/30 mL single-dose vials)
Drug ClassCD20-directed CD3 T-cell engagers
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Lunsumio (mosunetuzumab-axgb) Prescribing Information.2022Genetech Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines